Cribstone Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Cribstone Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-47,349	Closed	-$841K	–	785
2018 Q3	$841K	Hold	47,349	–	–	0.39%	63
2018 Q2	$653K	Hold	47,349	–	–	0.32%	65
2018 Q1	$430K	Hold	47,349	–	–	0.21%	85
2017 Q4	$203K	Hold	47,349	–	–	0.1%	128
2017 Q3	$67K	Hold	47,349	–	–	0.03%	220
2017 Q2	$71K	Buy	47,349 +19,208	+68%	+$41.2K	0.04%	222
2017 Q1	$66K	Hold	28,141	–	–	0.04%	246
2016 Q4	$63K	Sell	28,141 -19,208	-41%	-$55.2K	0.04%	233
2016 Q3	$142K	Hold	47,349	–	–	0.09%	138
2016 Q2	$152K	Buy	47,349 +14,808	+46%	+$54.3K	0.09%	132
2016 Q1	$101K	Hold	32,541	–	–	0.08%	101
2015 Q4	$130K	Buy	+32,541	New	+$150K	0.11%	99

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Cribstone Capital Management's ECYT Position: Q4 2018 in Review

Cribstone Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 47,349 shares — an estimated $841K sold.

Cribstone Capital Management first reported a position in ECYT in Q4 2015 and held it in 12 quarters. The position peaked at $841K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Cribstone Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Cribstone Capital Management sold 47,349 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $841K.
Cribstone Capital Management first reported a position in Endocyte, Inc. Common Stock in Q4 2015 and held it in 12 quarters.
Cribstone Capital Management's Endocyte, Inc. Common Stock position peaked at $841K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Cribstone Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.